Ligand Buys Into Ongoing Partnerships With Icagen Deal

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Ligand gets ongoing drug development collaborations with Roche and CFF, six novel preclinical compounds and sodium ion channel technology platform capabilities in acquiring Icagen’s North Carolina operations.

Perfect business partnership as a connecting puzzle shaped as two trees in the form of human heads connecting together as a corporate success metaphor for cooperation and agreement as equal partners.
Ligand says Icagen assets will enhance its business model, yield revenue

Ligand Pharmaceuticals Inc. unveiled an agreement to acquire all core assets of ICAgen Inc.’s North Carolina operations – including programs partnered with Roche and the Cystic Fibrosis Foundation – on 12 February. The announcement came a week after Ligand told investors it has between $500m and $750m to consummate deals that will add to its technological capabilities and bring in revenue-creating opportunities.

San Diego-based Ligand will pay $15m in cash for the Icagen assets, which include an early-stage neurology collaboration with Roche,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.